COSCIENS Biopharma Inc. (CSCIF) Form 6-K — Jun 18, 2026

Shareholders approved all proposals at the annual general meeting, including the re-election of the board of directors and the re-appointment of Deloitte LLP as auditors. Peter H. Puccetti, who served as Interim CEO since November, was appointed permanent President and Chief Executive Officer effective immediately. The meeting also authorized a share capital amendment involving a consolidation of common shares on a 1-for-150 basis followed by a 50-for-1 split.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.